|
1
|
Forman D and Burley VJ: Gastric cancer:
global pattern of the disease and an overview of environmental risk
factors. Best Pract Res Clin Gastroenterol. 20:633–649. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5(Suppl 1): S5–S11. 2002. View Article : Google Scholar
|
|
3
|
Shin HR, Jung KW, Won YJ and Park JG; 139
KCCR-affiliated Hospitals. 2002 annual report of the Korea Central
Cancer Registry: based on registered data from 139 hospitals.
Cancer Res Treat. 36:103–114. 2004. View Article : Google Scholar
|
|
4
|
Kelley JR and Duggan JM: Gastric cancer
epidemiology and risk factors. J Clin Epidemiol. 56:1–9. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun XD, Mu R, Zhou YS, et al: Analysis of
mortality rate of stomach cancer and its trend in twenty years in
China. Zhonghua Zhong Liu Za Zhi. 26:4–9. 2004.(In Chinese).
|
|
6
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rivera F, Vega-Villegas ME and López-Brea
MF: Chemotherapy of advanced gastric cancer. Cancer Treat Rev.
33:315–324. 2007. View Article : Google Scholar
|
|
8
|
Arceci RJ: Tumor cell survival and
resistance to therapy. Curr Opin Hematol. 3:279–287. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Filipits M: Mechanisms of cancer:
multidrug resistance. Drug Discov Today Dis Mech. 1:229–234. 2004.
View Article : Google Scholar
|
|
10
|
Xia L, Zhang D, Du R, et al: miR-15b and
miR-16 modulate multidrug resistance by targeting BCL2 in human
gastric cancer cells. Int J Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi Y, Zhai H, Wang X, et al: Ribosomal
proteins S13 and L23 promote multidrug resistance in gastric cancer
cells by suppressing drug-induced apoptosis. Exp Cell Res.
296:337–346. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao Y, You H, Liu F, et al:
Differentially expressed gene profiles between multidrug resistant
gastric adenocarcinoma cells and their parental cells. Cancer Lett.
185:211–218. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiseki M, Nagashima M, Pedeux RM, et al:
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.
Cancer Res. 63:2373–2378. 2003.PubMed/NCBI
|
|
14
|
He GH, Helbing CC, Wagner MJ, Sensen CW
and Riabowol K: Phylogenetic analysis of the ING family of PHD
finger proteins. Mol Biol Evol. 22:104–116. 2005.PubMed/NCBI
|
|
15
|
Aasland R, Gibson TJ and Stewart AF: The
PHD finger: implications for chromatin-mediated transcriptional
regulation. Trends Biochem Sci. 20:56–59. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Wang KS, Wang ZQ, et al: Nuclear
localization signal of ING4 plays a key role in its binding to p53.
Biochem Biophys Res Commun. 331:1032–1038. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim S, Chin K, Gray JW and Bishop JM: A
screen for genes that suppress loss of contact inhibition:
identification of ING4 as a candidate tumor suppressor gene in
human cancer. Proc Natl Acad Sci USA. 101:16251–16256. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim S, Welm AL and Bishop JM: A dominant
mutant allele of the ING4 tumor suppressor found in human
cancer cells exacerbates MYC-initiated mouse mammary
tumorigenesis. Cancer Res. 70:5155–5162. 2010.
|
|
19
|
Zhang X, Xu LS, Wang ZQ, et al: ING4
induces G2/M cell cycle arrest and enhances the chemosensitivity to
DNA-damage agents in HepG2 cells. FEBS Lett. 570:7–12. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Unoki M, Shen JC, Zheng ZM and Harris CC:
Novel splice variants of ING4 and their possible roles in the
regulation of cell growth and motility. J Biol Chem.
281:34677–34686. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie Y, Zhang H, Sheng W, Xiang J, Ye Z and
Yang J: Adenovirus-mediated ING4 expression suppresses lung
carcinoma cell growth via induction of cell cycle alteration and
apoptosis and inhibition of tumor invasion and angiogenesis. Cancer
Lett. 271:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garkavtsev I, Kozin SV, Chernova O, et al:
The candidate tumour suppressor protein ING4 regulates brain tumour
growth and angiogenesis. Nature. 428:328–332. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J and Li G: Cell cycle regulator ING4
is a suppressor of melanoma angiogenesis that is regulated by the
metastasis suppressor BRMS1. Cancer Res. 70:10445–10453. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Colla S, Tagliaferri S, Morandi F, et al:
The new tumor-suppressor gene inhibitor of growth family member 4
(ING4) regulates the production of proangiogenic molecules by
myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α)
activity: involvement in myeloma-induced angiogenesis. Blood.
110:4464–4475. 2007.PubMed/NCBI
|
|
25
|
Ling C, Xie Y, Zhao D, Zhu Y, Xiang J and
Yang J: Enhanced radiosensitivity of non-small-cell lung cancer
(NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther.
19:697–706. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie Y, Sheng W, Miao J, Xiang J and Yang
J: Enhanced antitumor activity by combining an adenovirus harboring
ING4 with cisplatin for hepatocarcinoma cells. Cancer Gene Ther.
18:176–188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishikawa T, Ramesh R, Munshi A, Chada S
and Meyn RE: Adenovirus-mediated mda-7 (IL24) gene therapy
suppresses angiogenesis and sensitizes NSCLC xenograft tumors to
radiation. Mol Ther. 9:818–828. 2004.
|
|
28
|
Zhang X, Cheung RM, Komaki R, Fang B and
Chang JY: Radiotherapy sensitization by tumor-specific TRAIL
gene targeting improves survival of mice bearing human non-small
cell lung cancer. Clin Cancer Res. 11:6657–6668. 2005.PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kong D, Ma S, Liang B, et al: The
different regulatory effects of p53 status on multidrug resistance
are determined by autophagy in ovarian cancer cells. Biomed
Pharmacother. 66:271–278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Touchefeu Y, Harrington KJ, Galmiche JP
and Vassaux G: Review article: gene therapy, recent developments
and future prospects in gastrointestinal oncology. Aliment
Pharmacol Ther. 32:953–968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu W, Shan X, Wang T, Shu Y and Liu P:
miR-181b modulates multidrug resistance by targeting BCL2 in human
cancer cell lines. Int J Cancer. 127:2520–2529. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moon C, Oh Y and Roth JA: Current status
of gene therapy for lung cancer and head and neck cancer. Clin
Cancer Res. 9:5055–5067. 2003.PubMed/NCBI
|
|
34
|
Gunduz M, Nagatsuka H, Demircan K, et al:
Frequent deletion and down-regulation of ING4, a candidate tumor
suppressor gene at 12p13, in head and neck squamous cell
carcinomas. Gene. 356:109–117. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fang F, Luo LB, Tao YM, Wu F and Yang LY:
Decreased expression of inhibitor of growth 4 correlated with poor
prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers
Prev. 18:409–416. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang QS, Li M, Zhang LY, et al:
Down-regulation of ING4 is associated with initiation and
progression of lung cancer. Histopathology. 57:271–281. 2010.
|
|
37
|
Tapia C, Zlobec I, Schneider S, et al:
Deletion of the inhibitor of growth 4 (ING4) tumor
suppressor gene is prevalent in human epidermal growth factor 2
(HER2)-positive breast cancer. Hum Pathol. 42:983–990. 2011.
|
|
38
|
Hodorová I, Rybárová S, Vecanová J, Solár
P, Plank L and Mihalik J: Relation between expression pattern of
wild-type p53 and multidrug resistance proteins in human
nephroblastomas. Acta Histochem. 115:273–278. 2013.PubMed/NCBI
|
|
39
|
Camassei FD, Arancia G, Cianfriglia M, et
al: Nephroblastoma: multidrug-resistance P-glycoprotein expression
in tumor cells and intratumoral capillary endothelial cells. Am J
Clin Pathol. 117:484–490. 2002. View Article : Google Scholar
|
|
40
|
Yin F, Shi YQ, Zhao WP, Xiao B, Miao JY
and Fan DM: Suppression of P-gp induced multiple drug resistance in
a drug resistant gastric cancer cell line by overexpression of Fas.
World J Gastroenterol. 6:664–670. 2000.PubMed/NCBI
|
|
41
|
Sarkadi B, Ozvegy-Laczka C, Német K and
Váradi A: ABCG2 - a transporter for all seasons. FEBS Lett.
567:116–120. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Norris MD, Bordow SB, Marshall GM, Haber
PS, Cohn SL and Haber M: Expression of the gene for
multidrug-resistance-associated protein and outcome in patients
with neuroblastoma. N Engl J Med. 334:231–238. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sakaeda T, Nakamura T, Horinouchi M, et
al: MDR1 genotype-related pharmacokinetics of digoxin after single
oral administration in healthy Japanese subjects. Pharm Res.
18:1400–1404. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hait WN and Yang JM: The individualization
of cancer therapy: the unexpected role of p53. Trans Am Clin
Climatol Assoc. 117:85–101. 2006.PubMed/NCBI
|
|
45
|
Danial NN and Korsmeyer SJ: Cell death:
critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li K, Lu Y, Liang J, et al: RhoE enhances
multidrug resistance of gastric cancer cells by suppressing Bax.
Biochem Biophys Res Commun. 379:212–216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Adida C, Crotty PL, McGrath J, Berrebi D,
Diebold J and Altieri DC: Developmentally regulated expression of
the novel cancer anti-apoptosis gene survivin in human and mouse
differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
|
|
48
|
Altieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
